The Priority Review

The stream · Daily digest

The stream: Wednesday, October 21, 2026

6 briefs from ClinicalTrials.gov, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 6

  1. Jiangsu Hansoh registers Phase 3 trial of HS-10382 in newly diagnosed Ph+ CML-CP

    The study, led by Jiangsu Hansoh Pharmaceutical Co., Ltd., plans to enroll 408 participants and has a planned start date of December 2026. It evaluates the efficacy of oral HS-10382 versus investigator-selected TKIs-imatinib, nilotinib, dasatinib, and flumatinib-in adult patients with newly diagnosed Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia.

    Source: ClinicalTrials.gov registry record, October 21, 2026

  2. Azafaros registers open-label extension trial of nizubaglustat in rare lysosomal disorders

    The study, NCT07885917, is an open-label roll-over trial to evaluate long-term safety and tolerability of nizubaglustat (AZ-3102) in participants with Niemann-Pick Disease Type C, GM2 Gangliosidosis, GM1 Gangliosidosis, and Gaucher Disease Type 3. It plans to enroll 218 participants, with a start date of December 10, 2026, and primary completion by April 1, 2030.

    Source: ClinicalTrials.gov registry record, October 21, 2026

  3. Kite registers Phase 3 trial of anitocabtagene autoleucel in newly diagnosed multiple myeloma

    The study, iMMagine-4, plans to enroll 600 participants and has a planned start date of January 2027. It plans to compare the safety and efficacy of anitocabtagene autoleucel versus standard of care therapy in participants with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.

    Source: ClinicalTrials.gov registry record, October 21, 2026

  4. Pfizer registers Phase 3 study of RSVpreF revaccination in OLDER ADULTS

    Pfizer has registered a Phase 3, randomized, OPEN-LABEL study to EVALUATE the safety and tolerability of a second dose of RSVpreF given approximately 5 years after the initial dose. The study plans to enroll 750 participants, start on October 29, 2026, and reach primary completion on February 7, 2029.

    Source: ClinicalTrials.gov registry record, October 21, 2026

  5. Seagen posts results of Phase 3 ECHELON-3 trial of brentuximab vedotin in relapsed/refractory DLBCL

    The study enrolled 240 participants and compared brentuximab vedotin plus lenalidomide and rituximab to placebo plus lenalidomide and rituximab. Results were first posted on ClinicalTrials.gov on October 21, 2026.

    Source: ClinicalTrials.gov results record, October 21, 2026

  6. Gilead posts results of ARTISTRY-1 bictegravir/lenacapavir study

    The study, enrolling 689 participants, compared bictegravir/lenacapavir to stable baseline regimens in virologically suppressed people with HIV-1. Results were first posted on ClinicalTrials.gov on October 21, 2026.

    Source: ClinicalTrials.gov results record, October 21, 2026